首页> 外文OA文献 >Anti-HER-2 Bispecific Antibody KN026

【2h】

Anti-HER-2 Bispecific Antibody KN026

机译：抗HER-2双特异性抗体KN026

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 339?Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors [J] . Jifang Gong, Zhi Dong, Dan Liu, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：339？KN026（HER2-靶向双特异性抗体）与KN046（抗PD-L1 / CTLA-4双特异性抗体组合）的初步安全性，耐受性和功效结果，患者（PTS）与HER2似象肿瘤
2. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc|[gamma]|RI |[times]| anti-HER-2|[sol]|neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer [J] . R Repp, H H van Ojik, T Valerius, British Journal of Cancer . 2003,第12期

机译：双特异性抗体MDX-H210（抗-Fc |γ| RI | [倍] |抗-HER-2 | [sol] | neu）联合Filgrastim（G-CSF）治疗I期临床试验晚期乳腺癌
3. Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974 [J] . Shiraiwa Hirotake, Narita Atsushi, Kamata-Sakurai Mika, Methods: A Companion to Methods in Enzymology . 2019,第期

机译：用常见轻链的双特异性抗体：抗CD3ε和抗GPC3双特异性抗体的鉴定和优化，ERY974
4. MODULATION OF HALF ANTIBODY AND AGGREGATE FORMATION IN A CHO CELL LINE EXPRESSING A BISPECIFIC ANTIBODY [C] . Natalia Gomez, Agatha Wieczorek, Fang Lu, Cell culture engineering conference . 2018

机译：表达双特异性抗体的CHO细胞系中半抗体和聚集体形成的调控
5. Investigating the Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates, T Cells and Bispecific Antibodies [D] . Khot, Antari . 2020

机译：调查抗体 - 药物缀合物，T细胞和双特异性抗体的药代动力学和药效学
6. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening [O] . Hok Seon Kim, Diana Ronai Dunshee, Angie Yee, -1

机译：拴系可变CL双特异性IgG：快速双特异性抗体筛选的抗体平台
7. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer [O] . Repp, R, van Ojik, H H, Valerius, T, 2003

机译：双特异性抗体MDX-H210（抗-FcγRI×抗-HER-2 / neu）联合Filgrastim（G-CSF）治疗晚期乳腺癌的I期临床试验
8. Generation and Preclinical Evaluation of Homodimeric Anti-Her-2 Antibodies [R] . Vitetta, E. S. 2002

机译：同源二聚体抗Her-2抗体的产生和临床前评估

代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号